Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
128M
-
Number of holders
-
107
-
Total 13F shares, excl. options
-
77.5M
-
Shares change
-
+358K
-
Total reported value, excl. options
-
$428M
-
Value change
-
-$4.04M
-
Put/Call ratio
-
0.29
-
Number of buys
-
71
-
Number of sells
-
-35
-
Price
-
$5.52
Significant Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q3 2023
122 filings reported holding CTKB - Cytek Biosciences, Inc. - Common Stock - $0.001 par value as of Q3 2023.
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) has 107 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 77.5M shares
of 128M outstanding shares and own 60.56% of the company stock.
Largest 10 shareholders include BlackRock Inc. (16.8M shares), BROWN CAPITAL MANAGEMENT LLC (13.6M shares), VANGUARD GROUP INC (11.1M shares), RA CAPITAL MANAGEMENT, L.P. (6.81M shares), HHLR ADVISORS, LTD. (6.66M shares), STATE STREET CORP (3.78M shares), GEODE CAPITAL MANAGEMENT, LLC (2.35M shares), NEW YORK STATE COMMON RETIREMENT FUND (2.35M shares), WELLINGTON MANAGEMENT GROUP LLP (1.45M shares), and NORTHERN TRUST CORP (1.14M shares).
This table shows the top 107 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.